Etiket: LOTIS2
ADC Therapeutics announces updated results from the LOTIS-2 study to be presented at the 2023 European Hematology Association Hybrid Congress
shares in this article ADC Therapeutics SA (NYSE: ADCT) today announced that updated results from LOTIS-2, the pivotal Phase 2 clinical trial of ZYNLONTA® (loncastuximab-tesirin-Lpyl) in patients with relapsed/refractory diffuse…